Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On August 26, 2021, Jae B. Kim, M.D. informed Avidity Biosciences, Inc. (the "Company") of his intention to resign as Chief Medical Officer of the Company, effective August 30, 2021, for personal reasons. In connection with his resignation, the Company entered into a separation agreement with Dr. Kim, pursuant to which Dr. Kim, in exchange for a general release of claims and his agreement to various other customary restrictive covenants, will be eligible to receive certain severance benefits. The foregoing description of the separation agreement does not purport to be complete and is qualified in its entirety by reference to the separation agreement, which will be filed as an exhibit 10.1 to the Company's Form 10-Q to be filed for the quarter ending September 30, 2021, and is incorporated herein by reference.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses